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ABSTRACT
IS DEXAMETHASONE 4MG A MORE EFFECTIVE ANTI-EMETIC THAN
DEXAMETHASONE 8MG FOR THE PREVENTION OF EARLY
POST-OPERATIVE NAUSEA AND VOMITING IN WOMEN
UNDERGOING LAPAROSCOPIC GYNECOLOGICAL SURGERY?
by Steven Blake Doyle
December 2015
Postoperative nausea and vomiting (PONV) is a common problem in the surgical
setting. It affects as much as 20 to 80 percent of patients undergoing surgery (D'souza,
Swami, & Bhagwat, 2011). PONV can lead to increased patient costs and recovery time
by causing the patient to stay in the healthcare facility for a longer period of time. A
retrospective cohort study was completed to examine whether or not there was a
significant difference between patients who received 4mg and 8mg of dexamethasone in
the incidence of PONV. All patients studied received ondansetron intraoperatively as
their primary anti-emetic. English-speaking patients who met the following inclusion
criteria were included in the retrospective chart review: those who are female, those who
have undergone laparoscopic gynecological surgery and received dexamethasone, those
who are non-smokers, and those who are aged 18-60 with an American Society of
Anesthesiologists (ASA) score of II or less. Patients that met the following exclusion
criteria were not counted towards the chart review: those who are an ASA III or above,
those who did not follow the recommended fasting time prior to surgery, those with a
history of motion sickness, those with a history of PONV, those who are taking routine
anti-emetics, those whose are deaf, those who are blind, those who are smokers, and
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those outside the age range for 18-60 years. Statistical analysis using a Chi-Square test
was used to evaluate whether the patients receiving 4mg of dexamethasone experienced
more PONV that those who received 8mg.
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CHAPTER I
INTRODUCTION
Statement of the Problem
Post-operative nausea and vomiting (PONV) is a common problem in the
surgical settings. It affects as much as 20 to 80 percent of patients undergoing surgery
(D'souza, Swami, & Bhagwat, 2011). Sustained vomiting is one of the most frequent
causes of unexpected hospital admission of patients from ambulatory surgery centers
(Yao, Fontes, & Malhotra, 2012). PONV contributes to additional problems such as
anxiety, patient dissatisfaction, dehydration, muscular fatigue, and delayed recovery.
PONV has many different triggers. History of PONV, female gender,
laparoscopic procedures, opioids, being a non-smoker, and duration of surgery have all
been linked to increased incidence of PONV (Miller & Pardo, 2011). The chemoreceptor
trigger zone (CTZ) located in the brainstem is believed to be responsible for nausea and
vomiting. The CTZ contains opioid, serotonin, histamine, dopamine, and muscarinic
acetylcholine receptors, which when triggered, cause nausea and vomiting (Barash et al.,
2013). The CTZ, vagal nerve, and vestibular organs send signals to the vomiting center in
the medulla leading to PONV (Barash et al., 2013). A multimodal drug therapy approach
can be effective in blocking stimulation of the receptors of the CTZ, thus preventing
PONV.
There are many different approaches to preventing PONV. One particular method
that is popular is treating PONV prophylactically with the anti-emetic drug ondansetron.
It has been reported that many patients have greater fear of PONV than they do of
experience pain as a result of their procedure (Sweeny, 2003). If left untreated, the
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incidence PONV varies greatly amongst populations being studied, with an occurrence
rate of 20-30% in the general surgical population and as high as 70-80% in high-risk
surgical populations (Jee, Yoon, & Jang, 2010).
There are many different factors that can make a patient more or less susceptible
to experiencing PONV. Many of these risk factors can be identified by a thorough preanesthetic evaluation with a complete history and physical. One factor which can be
assessed is being obese. Obese patients have a higher incidence of PONV than non-obese
patients (Sweeny, 2003). Some explanation for this could be that anesthetic medications
could be deposited in adipose tissues and be released while the patient is in the recovery
room. Other problems with having a larger body size can be that larger people have
increased resting stomach volumes. The more volume one has in their stomach, the more
likely it is for that person to have an incidence of vomiting.
Gender plays a role in determining the risk factor of PONV. Women are four
times more likely to have PONV than men (Sweeny, 2003). This is even more likely to
occur in younger women due to the fact that the incidence of PONV also decreases with
age (Sweeny, 2003). These are major reasons why the proposed study is focusing on
women undergoing general anesthesia as the population of interest in regards to PONV
since they are more likely to experience it than men.
The type of surgical procedure can also have a major influence of PONV.
Gynecological and abdominal surgery patients are at a much greater risk of PONV than
patients undergoing other surgery types such as bone fracture repair. Some procedures
that are commonly associated with PONV are strabismus surgery, ear surgery,
laparoscopy, orchiopexy, ovum retrieval tonsillectomy, and breast surgery (Butterworth,
2

Mackey, & Wasnick, 2013). Considering which type of surgical procedure the patient is
undergoing can aid the anesthetist in making an assessment of how much the patient is at
risk for PONV.
The type of anesthetic used and the duration of the procedure also can play a role
in determining the risks of PONV. The longer the procedure, the greater the chance for
PONV. General anesthesia has a greater incidence of PONV. Nitrous oxide has also been
linked to increased incidence of PONV, as well as the use of opioids for pain
management (Sweeny, 2003).
There are several things, such as age, gender, duration of surgery, and body
weight that cannot be controlled by the anesthetist to prevent the incidence of PONV.
However, there are some factors that can be controlled such as fluid replacement and
which anesthetic agents are used throughout the procedure (Sweeny, 2003) . It is
important to note how much fluid the anesthetist is giving the patient during the preoperative, intraoperative, and postoperative state. Although there have been numerous
studies seeking to define fluid strategy, anesthetists giving liberal, standard, or restrictive
amounts of fluids have not been able to consistently improve postoperative outcomes
(Butterworth, Mackey, & Wasnick, 2013). As always, when considering fluid
resuscitation, the anesthetist should consider the patient’s comorbidities such as
cardiovascular history when selecting a fluid resuscitation strategy.
The anti-emetic drug ondansetron is a popular drug of choice for most anesthetists
in preventing and treating PONV. Ondansetron selectively block serotonin 5-HT
receptors with minimal to no effect on dopamine receptors (Butterworth, Mackey, &
Wasnick, 2013). 5-HT receptors appear to play an important role in the initiation of the
3

vomiting reflex. These receptors are located outside of the blood-brain barrier, which are
activated by substances such as anesthetics and opioids (Butterworth, Mackey, &
Wasnick, 2013). Thus the use of ondansetron is very effective in offsetting the emetic
effects of most drugs given during anesthesia. Ondansetron is metabolized in the liver via
cytochrome P-450 enzymes, and it is important to consider the dosage in patients who
have any signs of liver failure as to avoid toxicity (Butterworth, Mackey, & Wasnick,
2013). Ondansetron in a dosage of 4mg has been seen to be just as effective as 8mg when
it is administered in the post-anesthesia care unit for treatment of nausea and vomiting
(Nagelhout & Plaus, 2014).
Dexamethasone is a glucocorticoid steroid drug that has been found to be an
effective treatment in reducing the incidence of PONV, given alone or in combination
with other anti-emetic drugs (Nagelhout & Plaus, 2014). Dexamethasone should be
given immediately after induction instead of at the end of surgery, and the mechanism of
action in preventing PONV is unknown (Butterworth, Mackey, & Wasnick, 2013). The
beneficial effects of dexamethasone in preventing PONV could be secondary to its long
duration of action, which can last up to 24 hours (Nagelhout & Plaus, 2014).
Dexamethasone in doses as small as 4mg has been shown to be as effective as
ondansetron in reducing the incidence of PONV (Butterworth, Mackey, & Wasnick,
2013). Dexamethasone at a dosage of 4mg and 8mg have been shown to prevent PONV
(D'souza, Swami, & Bhagwat, 2011). Dexamethasone is commonly supplied in 4mg/1ml
vials.
As with ondansetron, dexamethasone is also metabolized in the liver via
cytochrome P-450 enzymes. Adverse effects of single dose of dexamethasone have not
4

been reported, however, patients who are sensitive to steroid administration, such as
patients with diabetes, should be considered carefully as steroids have a tendency to
increase blood glucose levels (Nagelhout & Plaus, 2014). Dexamethasone also acts in the
inhibition of prostaglandin synthesis thus preventing swelling, which could prove
especially useful to surgeons and anesthetists during neck and airway procedures
(Nagelhout & Plaus, 2014).
Conceptual and Theoretical Framework
The use of prescriptive theory, including its basic tenets, assumptions, and theory
parts, will serve as a theoretical framework for the capstone project involving the use of
dexamethasone intravenously for the prevention of post-operative nausea and vomiting.
Future practice implications of prescriptive theory are abundant, as most experiments
measuring interventions can be applied to prescriptive theory.
Prescriptive theory is a subclass of a group of theories known as middle range
theories. When theorists produced middle-range theories, they chose conceptual models
that align with his or her own expectations of the world. Many middle range theories are
created from the same conceptual model (Butts & Rich, 2011). According Butts and
Rich, “Many middle-range theories are needed to deal with all of the phenomena
encompassed by any one conceptual model because each theory deals with only a limited
aspect of the total reality encompassed by a conceptual model” (p.36). Middle-ranged
theories can further be broken down into subclasses. McKenna and Slevin outlined four
types of scientific categories, descriptive, explanatory, prescriptive, and finally
prescriptive theory (Butts & Rich, 2011). Prescriptive theory prescribes evidence and
uses knowledge utilization that looks beyond the predictive cause-and-effect
5

relationships. Prescriptive theory builds on other the other subclasses of middle-range
theory that consists of descriptive, explanatory, and predictive theory (Butts & Rich,
2011). The adaptation of prescriptive theory could aid clinicians by providing evidence of
cause-and-effect relationships between interventions, such as intravenous administration
of dexamethasone, to predict outcomes like the prevention of PONV. In other words,
prescriptive theory addresses aspects of therapeutic interventions. This capstone project,
as previously described, will be addressing a pharmacological intervention in the
prevention of PONV. The administration of dexamethasone to prevent PONV uses
prescriptive theory by exploring cause-and-effect relationships, and investigating whether
or not the intervention of administering dexamethasone intravenously is effective in
preventing PONV. Evidence of the effectiveness or ineffectiveness of these interventions
will be noted in order to influence current practice.
Review of Literature
Included in this section is a narrative review of literature concerning the use of
dexamethasone in the prevention of PONV within various populations. The online
database CINAHL and PubMed, were used to search for articles related to the clinical
question at hand. The word “dexamethasone” was entered into line one, the words
“postoperative nausea and vomiting” were entered into line two, and the word “women”
was entered into line three. A total of 91 articles were found from CINAHL and 71
articles from PubMed. Ten articles were used exclusively for the literature review that
exclusively included the population of women aged 18 or older undergoing general
anesthesia.
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Gynecological surgery is considered a high risk factor for PONV (D'souza,
Swami, & Bhagwat, 2011). A quantitative study by D’souza, Swami, and Bhagwat
(2011) compared the use of intravenous dexamethasone and ondansetron for the
prevention of PONV in young women undergoing laparoscopic gynecological surgery.
Ninety-three women were randomly divided into 3 groups. One group received 4mg
dexamethasone, another group 8 mg dexamethasone, and the final group received 4 mg
of ondansetron. A PONV score was used as an assessment tool during the first 24 hours
after surgery.
The incidence of PONV during the 24 hour postoperative period was highest
amongst the group that received 4 mg ondansetron within the first 3 hours
postoperatively. In the dexamethasone 4 mg groups, the request for rescue antiemetic
drugs was significantly lower than in the dexamethasone 8mg group and the ondansetron
4mg group. Based on this study, it can be suggested that dexamethasone is an efficient
cost effective drug for the prophylaxis of PONV, and the dexamethasone at a dosage of
4mg was most effective amongst this population.
Laparoscopic surgeries are the second most common cause of PONV (Maddali,
Fahr, Fahr, & Zarrough, 2003) A comparison of dexamethasone with ondansetron against
metoclopramide and dexamethasone for the prevention of PONV amongst female
patients undergoing laparoscopic diagnostic gynecological surgery was examined by
Maddali, Mathew, Fahr, and Zarroug (2003). Their research was conducted in the form of
a perspective, randomized, double-blind study. One-hundred twenty women were given
either saline (group 1), 8mg of dexamethasone with 10mg of metoclopramide (group 2),
or 8mg dexamethasone with 4mg of ondansetron (group 3). There were no significant
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differences amongst the group’s mean age, mean weight, duration of procedure, or
duration of stay in the post anesthesia care unit (PACU). The patients were assessed for
PONV every hour for 6 hours, then every 2 hours for 6 hours, and finally every 4 hours
for the final 12 hours.
Between the three groups, the results of the study were most favorable for the
patients in group 3. The patients in group 1 suffered the highest incidence of nausea at
45%, followed by group 2 at 40%, and group 1 at 17.5%. Interestingly enough, patients in
group 1 did not suffer from vomiting, while 35% of group 2 and 10% of group 1 had
incidence of vomiting. The researchers concluded that the use of dexamethasone with
ondansetron as an efficient, cost-effective, and easily available way to prevent PONV
than the use of dexamethasone with metoclopramide (Maddali, Fahr, Fahr, & Zarrough,
2003).
The use of dexamethasone vs ketorolac for the prevention of PONV in women
undergoing laparoscopic gynecologic surgeries was examined in a by Rimaitis, Svitojute,
and Macas (2010). The researchers compared 153 women with American Society of
Anesthesiologists (ASA) physical status score of I-II undergoing laparoscopic
gynecological procedures. The women were divided into 3 random groups, a
dexamethasone group, a ketorolac group, and a control group. The dosage of
dexamethasone given was 4mg, while the ketorolac group received 30mg of ketorolac,
and the control group received no medication at all. There were no significant
demographic differences found within the population. Thirty-seven of the patients
registered had a history of migraines. Fifty-nine and one-half percent of these patients
suffered from PONV, while only 12.9% of patients without a history of migraine
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headaches reported PONV. Of the groups examined, the dexamethasone group had
13.8% of patients reporting PONV, while the ketorolac group had 37.3% of patients
report PONV, and the control group suffered a rate of 58.9% of patients reporting PONV.
The researchers concluded that history of migraine headache is an independent risk factor
for PONV, 4 mg of dexamethasone during induction of anesthesia showed a significant
difference in the reduction of PONV, and that the use of ketorolac during induction
reduced the risk of PONV.
It is well known that ondansetron is an effective anti-emetic drug. Yuksek, Alici,
Erdem, and Cesur (2003) sought to compare ondansetron vs dexamethasone for the
prevention of PONV in women undergoing laparoscopic gynecological surgery. The
study consisted of women aged 19-62 years old undergoing general anesthesia for
laparoscopic gynecological surgery. Patients with BMI > 35, history of gastric reflux
were excluded. All patients completed the study.
The 60 participants were randomly divided into 3 equal groups, one receiving
4mg ondansetron, the other 8mg dexamethasone, and the last given saline. There was a
significant difference seen between the groups during the first 3 hours after surgery.
Ondansetron was found to be significantly more effective than dexamethasone and saline.
Dexamethasone did not prevent PONV nor did saline within the first 3 hours. In fact,
there were no significant differences found between the two. Based on this study, one
could suggest that dexamethasone was ineffective in preventing early PONV, and
ondansetron is the better choice to prevent PONV within the first 3 hours after surgery.
Laparoscopic cholecystectomy is a very common laparoscopic abdominal
procedure. While many studies have focused on the use of dexamethasone in
9

laparoscopic gynecological procedures, Choi, Jo, J. Lee, W. Lee, and Shim (2012) sought
to compare the use of dexamethasone 8mg, ramosetron 0.3 mg, and dexamethasone 8mg
combined with ramosetron 0.3mg in women undergoing laparoscopic cholecystectomy.
The researchers randomly assigned 120 women into 3 groups, each receiving one of the
mentioned drug regimens. The participants’ ages ranged from 21 to 64 years old, and had
an ASA status of I-II. The researchers concluded that the combination of both
dexamethasone and ramosetron was most effective in prevention of PONV, with 93% of
participants showing complete response, followed by ramosetron at 78% and
dexamethasone at 70%.
Breast surgery under general anesthesia has been linked to an increased incidence
of PONV. It is estimated that 60- 80% of patients having a mastectomy procedure with
axillary dissection experience PONV (Fujii, 2006). Dr. Yoshitaka Fujii (2006) reviewed
the use of dexamethasone as well as other traditional, non-traditional, and nonpharmacological preventative measures for PONV for women undergoing mastectomy
procedures. Fujii concluded that dexamethasone is effective for the prevention of PONV
for patients undergoing a mastectomy, especially during the first 24 hours, and that
dexamethasone is particularly effective when given in addition to other anti-emetics.
Fujii later used the knowledge gained from the review to collaborate with Dr.
Masahiro Nakayama (2007) to conduct a double-blind placebo-controlled trial to
determine the effectiveness of dexamethasone for the prevention of PONV and the
reduction of analgesic requirement in patients undergoing a mastectomy. Ninety women
aged 40-66 with no history of gastrointestinal disease, history of PONV, or motion
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sickness were randomly divided into three groups, one receiving 4mg dexamethasone,
another 8mg of dexamethasone, and the last a placebo.
Within 24 hours after the procedure, 33% of the dexamethasone 4mg patients
experienced PONV, followed by 27% in the dexamethasone 8mg group, and 67% in the
placebo group. The use of indomethacin as a pain reliever was requested by 83% of the
placebo group, 70% of those who received 4mg dexamethasone, and 45% of the
participants who received 8mg dexamethasone. The researchers suggested that
dexamethasone at a dosage of 8mg was most effective in decreasing the incidence of
PONV and pain in women undergoing general anesthesia for mastectomy.
Motion sickness has been shown to cause an increased risk for PONV in the
patient undergoing general anesthesia (Lee, Lai, Lin, Huang, & Lin, 2002). Lee et
al.(2002) completed a double-blind, placebo-controlled study in which 168 female
patients, half of which had a history of motion sickness, undertaking laparoscopic
gynecological surgery were randomly divided into 2 groups and given 8mg of
dexamethasone or saline immediately before induction of anesthesia.
The results of the study yielded complete response to dexamethasone in 80.5% of
patients with history of motion sickness and 37.5% of patients with history of motion
sickness who received saline. In contrast, a complete response to dexamethasone was
found in 83.3% of patients without history of motion sickness and 53.7% of those
receiving saline. Calculation of efficacy within the subgroups showed dexamethasone
was 45.3% more effective in patients with a positive history of motion sickness. In
conclusion, Lee et al. found that dexamethasone is effective in both groups of patients
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and that there were more favorable outcomes amongst patients who received
dexamethasone with a history of motion sickness.
Surgery type and population are not the only risk factors for PONV, the use of
narcotic drugs in the perioperative period can increase the risk of PONV. A quantitative
study by Young, Yoon, and Jang (2010) compared the use of ondansetron with
dexamethasone vs metoclopramide with dexamethasone in patients undergoing
gynecologic procedures who were also receiving fentanyl intravenous-patient controlled
analgesia. A total of 100 patients were randomly divided into two groups. One group
received 5mg dexamethasone after induction, and then was given 4 mg ondansetron at the
end of the procedure, while the other group was given 5 mg of dexamethasone after
induction with 20 mg metoclopramide at the end of the procedure.
The results of the study found no significant differences between the two
treatment modalities. The incidence of PONV was 44% in the group that received
ondansetron and dexamethasone, and 38% in the group that received metoclopramide and
dexamethasone. Both treatment modalities appeared to be effective in the prevention of
PONV.
The practitioner controls when to give medication. Correct timing of
administration of medication is essential to achieving the desired effects. Wang, Ho,
Tzeng, and Tang (2000) sought to determine optimal timing of the administration of
dexamethasone for the prevention of PONV. 120 ASA I-II women ages 35-45 scheduled
for total abdominal hysterectomy participated in a randomized, double-blind, placebocontrolled study. Those with a positive history of gastrointestinal disease or prior use of
antiemetics in the last 48 hours were excluded. The patients were randomly divided into 3
12

groups. Group 1 was given 10mg of dexamethasone prior to induction of anesthesia,
group 2 received 10 mg dexamethasone after tracheal extubation, and group 3 only
received saline. Within 2 hours post-operatively, only 8% of patients in group 1 needed
rescue anti-emetics, followed by 30% of group 2 and 35% of group 3. Incidence of
PONV during the first two hours post-operatively was present in 15% of group 1, 45% of
group 2, and 53% of group 3. During hours 2-24 PONV was reported in 25% of group 1,
28% of group 2, and 55% of group 3. Based on these results, it is clear to see that
dexamethasone should be given immediately before induction of anesthesia to achieve
maximum efficacy in the prevention of PONV.
In conclusion, numerous studies have indicated that dexamethasone is an efficient
drug for the prevention of PONV in women undergoing general anesthesia.
Dexamethasone at dosages of 4 and 8mg have both been shown to be effective, and
giving dexamethasone as an adjunct to ondansetron or other traditional antiemetics shows
favorable results. Evidence supports that dexamethasone is effective at preventing PONV
in high risk patients with history of motion sickness. It is most beneficial to give
dexamethasone at the induction of anesthesia, rather than at the end of surgery. None of
the studies reviewed reported any incidence unwanted side effects.
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CHAPTER II
METHODOLOGY
Target Outcome
The desired outcome of this capstone project is to determine whether or not there
is a significant difference between the dosages of dexamethasone in regards to the
prevention of PONV by completing a retrospective chart review. The knowledge gained
could help anesthesia providers determine the most effective dosage of dexamethasone
for their patients, which could in turn lead to cost savings by reducing the time spent in
the PACU, and result in greater patient satisfaction through the reduction of PONV. If no
significant difference is found, one could suggest that 4mg be administered instead of
8mg in order to use less medication.
Population
Fifty patient charts that met the inclusion criteria were selected from patients that
had laparoscopic gynecological surgery at a level 2 regional trauma center in the
Southeastern United States. Each patient selected received ondansetron during the
intraoperative period. English speaking patients who meet the following inclusion criteria
were included in the retrospective chart review: those who are female, those who have
underwent laparoscopic gynecological surgery and received dexamethasone, those who
are non-smokers, and those who are aged 18-60 with an ASA of II or less. Patients that
met the following exclusion criteria were not counted towards the chart review: those
who are an ASA III or above, those who did not follow the recommended fasting time
prior to surgery, those with a history of motion sickness, those with a history of PONV,
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those who are taking routine anti-emetics, those whose are deaf, those who are blind,
those who are smokers, and those outside the age range for 18-60 years.
Barriers
Clinical limitations to the accuracy of this retrospective chart review could
include that some patients are simply more prone to PONV than others. The use of a
retrospective chart study does not allow the researchers to give direct interventions, or
finely control the amount of drugs and intravenous fluids given throughout the
administration of anesthesia. Duration of surgical procedures can also vary, even if the
surgeon is performing the same procedure on two different patients. As mentioned
earlier, the longer the duration of surgery, the higher risk the patient is for PONV. There
was difficulty finding an adequate number of patients that had received 4mg
dexamethasone compared to 8mg. Eight mg dexamethasone was used by substantially
more providers at the host site. A larger sample could have been obtained had there been
a greater number of patients who received 4mg of dexamethasone.
Setting
A regional hospital in the Southeastern United States will serve as the setting for
the retrospective chart review. The hospital provides a large variety of surgical services
for its surrounding community. There are many surgeons who routinely perform
laparoscopic gynecological surgery within the setting. The hospital uses Electronic
Patient Integrated Care (EPIC), which is an electronic health record used to store patient
records. The use of EPIC was an additional bonus as it provided quick access to
numerous medical records allowing the researcher to efficiently collect the sample.
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Research Approaches
A retrospective chart review was completed in order to compare the outcomes of
the two medications. A retrospective review involves the researcher looking at a group of
patients who did or did not experience an event such as PONV. In the case of the study,
the incidence of PONV was examined among 2 different groups of patients, one who
received 4mg dexamethasone, and the other who received 8mg. A retrospective review
prevents the researcher from making direct interactions to the patients being studied. This
approach is deemed safe and appropriate as it allows anesthesia providers to care for their
patients in the way they prefer, and does not directly influence patient care. Data was
collected using the data collection form attached at the end of this paper. All data was deidentified to protect patients’ protected private information. Statistical Package for the
Social Sciences (SPSS) was used to make a statistical analysis which compared the data
by using a chi-square test to determine whether or not there is a significant difference
between the two dosages of medications in regards to early PONV.
Sampling
After given approval by the Institutional Review Board (IRB) at The University
of Southern Mississippi and the capstone setting, a retrospective chart review was
completed in order to collect data. Patients’ charts were searched using EPIC software.
Patient sensitive information was not recorded. The patient summary page on EPIC was
first used to see if the patient met the inclusion criteria. This page gives general
demographic information on the patient, and gives a snapshot of their overall health such
as co-morbidities, age, history of PONV or motion sickness, smoking status, and ASA
score as given by the anesthesia provider that interviewed them prior to their procedure.
16

Once that patient was deemed to have met all inclusion criteria and none of the exclusion
criteria, the intraprocedure record was accessed. The intraprocedure flowsheet provided
the researcher with the anesthetic agent used, amount of dexamethasone given, amount of
neostigmine given, intravenous fluids given, duration of anesthetic, and whether or not
ondansetron was given intraoperatively. After the patient was deemed to have been given
the appropriate intraoperative regimen for the study, the researcher then viewed the
PACU flowsheet record to the PACU in and out times. The electronic medication
administration record (EMAR) was then accessed to determine if any ondansetron or
promethazine was given during the patient’s time in the PACU. This served as an
indicator for the researcher for PONV in the PACU because these medications are only
given if the patient is experiencing nausea or vomiting.
In summary, de-identified relevant data, including patient age, gender, race,
anesthetic agent used, intravenous fluid administered, duration of anesthetic, and the
occurrence of early PONV in the post anesthesia care unit as evidenced by the
administration of rescue anti-emetics ondansetron and promethazine was collected. Fifty
patient charts were reviewed to compare dosages of dexamethasone used for each patient.
The two samples, one consisting of patients receiving 4mg dexamethasone, and the other
consisting of patients receiving 8mg of dexamethasone, were compared. Frequency of
PONV in the PACU among ages 18-30, 30-40, 40-50, and 50-60 was recorded. PONV in
the PACU amongst race and inhalation agent used were also examined. Pre-op
medications were also recorded as well as past history of PONV and motion sickness.
Intraoperative fluids given, amount of neostigmine, ondansetron, and dexamethasone
administered were also recorded and analyzed.
17

The pre-existing data collected from the healthcare facility for the project
contained protected patient health information. All information was kept confidential
throughout the collection and analysis of data. Patient identifiers such as the patient
medical record numbers were not recorded. After all data was recorded and statistical
analysis was completed, all data collection forms were shredded as requested by the IRB.
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CHAPTER III
ANALYSIS OF DATA
The goal of this capstone project was to perform a retrospective chart review to
determine whether or not there was a significant difference between two dosages of
dexamethasone in the prevention of PONV in the PACU. A Pearson’s chi-square test was
used to determine whether or not there was a statistical significant difference.
Demographic data was also collected as well as incidence of PONV among dosages of
neostigmine and anesthetic agents used.
Statistical Analysis
A Pearson’s chi-square test was completed using SPSS to make a statistical
analysis. The chi-square test helps distinguish whether or not there is a statistically
significant difference when comparing two different groups receiving the same
interventions. The chi-square test can provide the probability that the outcome and
exposure of an event are independent (Peat, Barton, & Elliott, 2012). In this particular
case, the fisher’s exact value was the most relevant value due to the fact that the
incidence of PONV was less than 5 in each group. The Fisher’s exact test is generally
used when one or more cells in a 2 x 2 table have an expected count of less than 5 (Peat,
Barton, & Elliott, 2012). A hypothesis and null hypothesis were created for the capstone
project. The hypothesis stated that there is a decreased incidence of early PONV in
patients receiving 8mg of dexamethasone vs 4mg of dexamethasone. The null hypothesis
stated that there is not a decreased incidence of early PONV in patients receiving 8mg of
dexamethasone vs 4mg of dexamethasone. The level of significance  a probability of
rejecting a true null hypothesis. An  value of 0.05 was used to analyze the data.
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Results
The retrospective review was completed at the approved healthcare facility in the
Southeastern United States. A convenience sample of 50 charts spanning February 2015
to September 2015 were analyzed. Inclusion criteria included those who are female, those
have underwent laparoscopic gynecological surgery and received dexamethasone, those
who are non-smokers, and those who are aged 18-60 with an ASA of II or less. Exclusion
criteria were not counted towards the chart review: those who are an ASA III or above,
those who did not follow the recommended fasting time prior to surgery, those with a
history of motion sickness, those with a history of PONV, those who are taking routine
anti-emetics, those whose are deaf, those who are blind, those who are smokers, and
those outside the age range for 18-60 years. All data was de-identified during the
collection process and destroyed after data analysis was complete. The following tables
summarize demographic data and findings within the sample group. Patient ages,
ethnicity, inhalation agent used, and amount of neostigmine were all examined.
Table 1
Patient Age and Incidence of PONV

Age

PONV 4mg

No PONV 4mg PONV 8mg

No PONV 8mg

18-29

1

1

0

1

30-39

0

10

0

9

40-49

1

7

3

8
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Table 1 (continued).
50-60

0

5

0

4

Of the 50 patients examined, most of the patients fell between the age groups of
30-49. This was anticipated before data collection began, as with most laparoscopic GYN
procedures such as hysterectomies and tubal ligations are performed on this age group.
Ethnicities of the recorded sample is illustrated in Table 2.
Table 2
Incidence of PONV among Ethnicity

Ethnicity

PONV 4mg

No PONV 4mg PONV 8mg

No PONV 8mg

White

1

18

3

17

Black

1

5

0

5

Table 3
Incidence of PONV among Inhalation Agent

Inhalation Agent

Sevoflurane

Desflurane

PONV

2

3

No PONV

35

10
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The use of sevoflurane at the capstone project data collection facility was clearly
the inhalation agent of choice by the anesthesia providers. It is interesting to note that a
large proportion of the patients who received desflurane experienced PONV in the
PACU. 23% of those who received desflurane experienced PONV, while only 5.4% of
those who received sevoflurane were positive for PONV in the PACU. The researcher
took notice of this outlier, however, due to the small sample size of this capstone, it
would not be a good candidate for statistical analysis of PONV among anesthetic agent
used.
Below, table 4 shows the amount of the paralytic reversal drug neostigmine was
given to each patient. Neostigmine is the most commonly used paralytic reversal agent
used, but it is believed to increase the incidence of PONV (Nagelhout & Plaus, 2014). In
the 5 incidences of PONV, 3 received 3 mg of neostigmine, and 2 received 4 mg of
neostigmine. It is interesting to note that the 6 patients from this sample who received 5
mg of neostigmine, which is the maximum recommended dosage, did not experience
PONV.
Table 4
Total Neostigmine Patients Received
Neostigmine (mg)

PONV

No PONV

0

0

9

1

0

1

2

0

4

3

3

11
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Table 4 (continued).
4

2

14

5

0

6

The data presented in table 5 below is indicative of the sample used in this study.
There were a total of 50 subjects analyzed during this retrospective chart review, 25
patients receiving 4mg of dexamethasone and 25 patients receiving 8mg of
dexamethasone. The incidence of PONV in the PACU occurred almost equally across
groups. 2 patients receiving 4mg experienced PONV while 3 patients receiving 8mg
experienced PONV. This accounts for 8% and 12 % of the groups being analyzed
respectively. Of all the patients measured from the population, 10% of the total
experienced PONV in the PACU
Table 5
Dexamethasone PONV Cross Tabulation
PONV
Yes
Dexamethasone 4mg

Count

No

Total

2

23

25

8.0%

92.0%

100.0%

40.0%

51.1%

50.0%

4.0%

46.0%

50.0%

% within
Dexamethasone
% within PONV
% of Total
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Table 5 (continued).
8mg

Count

3

22

25

12.0%

88.0%

100.0%

60.0%

48.9%

50.0%

6.0%

44.0%

50.0%

5

45

50

10.0%

90.0%

100.0%

100.0%

100.0%

100.0%

10.0%

90.0%

100.0%

% within
Dexamethasone
% within PONV
% of Total
Total

Count
% within
Dexamethasone
% within PONV
% of Total

The Pearson’s chi-square test below, where (N=50, df=1)= .222, p=.067, allows
the researcher to determine whether or not there is a statistically significant difference
between the two different dosages of dexamethasone in regards to PONV in the PACU
among the sample. The chi-square test for association was completed. Since two of the
cells were less than 5 due to the incidence of PONV being low, there was no statistical
association using the Pearson Chi-Square value. Instead, the Fisher’s Exact Test was used
in which it yielded a 1.0 on the 2 sided test and a 0.500 on the 1 sided test. These results
yielded no statistically significant relationship among the two dosages of dexamethasone
in the reduction of PONV.
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Table 6
Chi Square Tests
Asymptotic

Value
Pearson Chi-Square

df

Significance

Exact Sig.

Exact Sig.

(two-sided)

(two-sided)

(one-sided)

.222a

1

.637

.000

1

1.000

.224

1

.636

Continuity
Correctionb
Likelihood Ratio
Fisher's Exact Test

1.000

.500

Linear-by-Linear
.218

1

.641

Association
N of Valid Cases

50

a. df=degrees of freedom. 2 cells (50.0%) have expected count less than 5. The
minimum expected count is 2.50.
b. Computed only for a 2x2 table
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CHAPTER IV
SUMMARY
The purpose of this capstone project was to complete a retrospective chart review
to help determine whether or not there was a significant difference between two dosages
of dexamethasone and the reduction of PONV in the PACU. After all data was analyzed,
it was concluded that there was no statistically significant difference between the
incidences of PONV in the PACU among the sample provided. It is interesting to note
that of the 13 patients that were given desflurane, 23% experienced PONV in the PACU.
Of the 50 patients in the sample, only ten percent experienced PONV in the PACU. As
stated earlier, PONV affects as much as 20% to 80% of patients undergoing surgery. This
was a relatively lower than expected total due to the fact that the women analyzed in the
study were considered having a very high risk for PONV.
Recommendations
Although the sample size was relatively small and only covered a short time
period, it is recommended that the findings of this paper be further investigated,
especially in terms of PONV and anesthetic agent being used. According to the clinical
site pharmacy, dexamethasone is supplied to the clinical site in single dose 4mg vials that
cost $2.50 per vial. While this is not a high cost for a single administration, the
compounded cost of thousands of vials could be substantial, especially at a busy surgery
center. One could argue that since there was no statistically significant difference
between the two dosages of dexamethasone in this sample, that the anesthesia provider
administer just 4mg of dexamethasone for the prevention of PONV in order to conserve
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medication and reduce overall costs. This point can further be argued since there are
studies reporting that 4mg of dexamethasone has been found to be just as effective in the
reduction of PONV as 8mg. However, as all anesthesia providers know, not all cases call
for the same medication regimens. For procedures where swelling may be a concern,
giving 8mg of dexamethasone may be more suitable since it would aid in the reduction
swelling and still help reduce PONV.
Conclusion
In conclusion, this retrospective chart review produced no statistically significant
difference between 4mg of dexamethasone and 8mg of dexamethasone in the reduction of
PONV in the PACU within the sample provided. One could argue based on this sample
that the administration of 4mg was just as efficient as 8mg in the reduction of PONV. If
supply is low or cost is an issue, the use of 4mg dexamethasone could be used as an
effective adjunct in anti-emetic therapy. Currently, PONV will continue to be a problem
for patients undergoing surgery. A holistic approach in the prevention of PONV, where
fluids are monitored, amount of neostigmine is considered, and appropriate receptors in
the CTZ are blockaded is a good approach for anesthetist in the prevention of PONV.
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APPENDIX A
FORREST GENERAL HOSPITAL IRB APPROVAL LETTER

APPENDIX B
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THE UNIVERSITY OF SOUTHERN MISISSIPPI IRB APPROVAL LETTER

APPENDIX C
DOCTOR OF NURSING PRACTICE ESSENTIALS
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The Essentials of Doctoral Education of Advanced Nursing Practice
I.

Scientific Underpinnings for Practice


The use of prescriptive theory to assess cause and effect
relationships. The administration of dexamethasone 4mg vs 8mg in
the prevention of PONV uses cause and effect relationships to
draw a conclusion based on patient outcomes. The knowledge
gained from these outcomes can be used to influence anesthesia
practice.

II.

Organizational and Systems Leadership for Quality Improvement and
Systems Thinking


Research supports that the use of dexamethasone is effective in the
prevention of PONV. The use of dexamethasone for prevention of
PONV could improve patient outcomes, and quality of hospital
stay when the patient does not suffer from symptoms of PONV.

III.

Clinical Scholarship and Analytical Methods for Evidence-Based Practice


Evidence supports that dexamethasone decreases the incidence of
PONV in women undergoing general anesthesia. Once the
retrospective chart review is completed, data collected could
influence current practice.

IV.

Information Systems/Technology and Patient Care Technology for the
Improvement of Transformation of Health Care


The use of research databases searched during the literature review
will provide evidence used to help determine best practice use of
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dexamethasone for the prevention of PONV. The use of EPIC
during the retrospective chart review will also put emphasis on
patient care technology.
V.

Health Care Policy for Advocacy in Health Care


Evidence shows that dexamethasone prevents PONV in women
undergoing general anesthesia. This information could help
influence anesthesia providers to create facility policies involving
the use of dexamethasone for the prevention of PONV.

VI.

Interprofessional Collaboration for Improving Patient and Population
Health Outcomes


At the conclusion of the capstone projects, interprofessional
collaboration will occur as the results are shared with local
anesthesia providers that could be used to improve patient
population health outcomes.

VII.

Clinical Prevention and Population Health for Improving the Nation’s
Health


PONV is a common occurrence in the surgical setting, and is more
likely to occur in women undergoing general anesthesia.
Decreased incidence of PONV will reduce costs for the patient and
healthcare facility providing care. The use of dexamethasone can
help achieve this.

VIII.

Advanced Nursing Practice
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This capstone puts emphasis on the use of the evaluation of
evidence-based literature to make a clinical decision for treatment
in the prevention of PONV demonstrating advanced levels of
clinical judgment to improve patient outcomes.

APPENDIX D
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ASA PHYSICAL STATUS CLASSIFICATION SYSTEM
ASA PS
Classification

Definition

Examples, including, but not limited to:

ASA I

A normal healthy
patient

Healthy, non-smoking, no or minimal alcohol use

ASA II

A patient with
mild systemic
disease

Mild diseases only without substantive functional
limitations. Examples include (but not limited to): current
smoker, social alcohol drinker, pregnancy, obesity (30 < BM
< 40), well controlled DM/HTN, mild lung disease

ASA III

A patient with
severe systemic
disease

Substantive functional limitations; One or more moderate to
severe diseases. Examples include (but not limited to):
poorly controlled DM or HTN, COPD, morbid obesity (BMI
≥40), active hepatitis, alcohol dependence or abuse,
implanted pacemaker, moderate reduction of ejection
fraction, ESRD undergoing regularly scheduled dialysis,
premature infant PCA < 60 weeks, history (>3 months) of
MI, CVA, TIA, or CAD/stents.

ASA IV

A patient with
severe systemic
disease that is a
constant threat to
life

Examples include (but not limited to): recent ( < 3 months)
MI, CVA, TIA, or CAD/stents, ongoing cardiac ischemia or
severe valve dysfunction, severe reduction of ejection
fraction, sepsis, DIC, ARD or ESRD not undergoing
regularly scheduled dialysis

ASA V

A moribund
patient who is not
expected to
survive without
the operation

Examples include (but not limited to): ruptured
abdominal/thoracic aneurysm, massive trauma, intracranial
bleed with mass effect, ischemic bowel in the face of
significant cardiac pathology or multiple organ/system
dysfunction

ASA VI

A declared braindead patient
whose organs are
being removed for
donor purposes

*The addition of “E” denotes Emergency surgery: (An emergency is defined as existing when delay in treatment of the patient would
lead to a significant increase in the threat to life or body part) (American Society of Anesthesiologists, 2015)

APPENDIX E
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DATA COLLECTION FORM
Identification # __________

Procedure Date
__/__/____

Age _______ Sex M / F

Ht. _____ Wt. _______

Ethnicity ______________

Smoker Y/N

BMI ________

ASA __________

Current Medications
______________________________________________________
Past Medical
History_______________________________________________________

Past Anesthesia Complications
______________________________________________
Preoperative
Medications___________________________________________________
Anes Start _____________

Anes End _____________

Total Anes
____________

Surgery Start ___________

Surgery End
___________

Total Surgery
__________

Intraoperative:
ETT size_____
Time

Inhalation agent used ______

Medication

Dose

Ondansetron
Dexamethasone
Neostigmine

IVF type: _____________
EBL __________ml
34

PACU:
PACU Vital Signs:
BP _____ HR _____ Temp ______
PACU time in: _________
Time

Medication

Dose

Ondansetron
Promethazine
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